FANCL: A Potential Drug Target and Biomarker for E3 Ubiquitin-Protein Ligase

Target Name: FANCL

NCBI ID: G55120

FANCL

FANCL: A Potential Drug Target and Biomarker for E3 Ubiquitin-Protein Ligase

Ubiquitin-protein ligase (E3) is a crucial enzyme in the ubiquitin system, which is responsible for regulating protein degradation in the cell. FANCL (isoform 2) is an E3 ubiquitin-protein ligase that has been identified as a potential drug target and biomarker. In this article, we will discuss the structure, function, and potential clinical applications of FANCL.

Structure and Function

FANCL is a 21-kDa protein that contains 21 amino acid residues. It has a characteristic Rossmann-fold structure that is commonly found in proteins that bind nucleotides. FANCL has a single catalytic active site and a distinct N-terminus that is involved in its N-linker interactions.

FANCL functions as an E3 ubiquitin-protein ligase by catalyzing the formation of a disulfide bond between the N-terminal amino acid residue of Ub8 and the C-terminal amino acid residue of Ub16. This reaction is critical for the regulation of protein stability and dynamics.

FANCL has been shown to play a critical role in the ubiquitin system in various cellular processes, including cell growth, apoptosis, and inflammation. For example, FANCL has been shown to be involved in the regulation of cell cycle progression and the hallmark of apoptosis, which is the process of cell death.

FANCL is also involved in the regulation of protein degradation, which is a critical process for maintaining cellular homeostasis. By catalyzing the formation of a disulfide bond between Ub8 and Ub16, FANCL promotes the ubiquitination of target proteins, which is then processed by other enzymes in the ubiquitin system.

Potential Clinical Applications

FANCL is a potential drug target due to its involvement in various cellular processes that are important for human health and disease. As a result, several studies have investigated the effects of drugs that inhibit FANCL activity.

One of the most promising drugs that has been shown to inhibit FANCL activity is rapamycin. Rapamycin is an immunosuppressant drug that is used to prevent the rejection of transplanted organs. It has been shown to inhibit FANCL activity by binding to the FANCL catalytic active site and preventing the formation of the disulfide bond between Ub8 and Ub16.

Another potential drug that has been shown to inhibit FANCL activity is QIQ-1042. QIQ-1042 is an inhibitor of FANCL activity that is currently in clinical trials for the treatment of various diseases, including cancer.

FANCL is also a potential biomarker for several diseases, including cancer. due to its involvement in the regulation of cell cycle progression and protein degradation, FANCL has been shown to be aberrantly expressed in various types of cancer. Therefore, FANCL has the potential to serve as a diagnostic marker for cancer and as a target for cancer therapies.

Conclusion

FANCL is a crucial enzyme in the ubiquitin system that plays a critical role in regulating protein stability and dynamics. Its role in various cellular processes makes it an attractive target for drug development. The inhibition of FANCL activity by drugs such as rapamycin and QIQ-1042, as well as its potential use as a biomarker for cancer, make FANCL a promising area of research for the future.

Protein Name: FA Complementation Group L

Functions: Ubiquitin ligase protein that mediates monoubiquitination of FANCD2 in the presence of UBE2T, a key step in the DNA damage pathway (PubMed:12973351, PubMed:16916645, PubMed:17938197, PubMed:19111657, PubMed:24389026). Also mediates monoubiquitination of FANCI (PubMed:19589784). May stimulate the ubiquitin release from UBE2W. May be required for proper primordial germ cell proliferation in the embryonic stage, whereas it is probably not needed for spermatogonial proliferation after birth

The "FANCL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FANCL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets